Home » Stocks » FGEN

FibroGen, Inc. (FGEN)

Stock Price: $13.27 USD -0.37 (-2.71%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $13.28 +0.01 (0.08%) Jul 23, 7:54 PM
Market Cap 1.22B
Revenue (ttm) 190.35M
Net Income (ttm) -182.70M
Shares Out 91.69M
EPS (ttm) -2.01
PE Ratio n/a
Forward PE 61.35
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $13.27
Previous Close $13.64
Change ($) -0.37
Change (%) -2.71%
Day's Open 13.65
Day's Range 13.11 - 13.73
Day's Volume 1,725,160
52-Week Range 13.11 - 57.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Eluminex Biosciences (Suzhou) Limited has exclusively licensed global rights to develop and commercialize a biosynthetic cornea from FibroGen Inc (NASDAQ: FGEN). The biosynthetic cornea is derived from ...

6 days ago - Benzinga

SUZHOU, China and SAN FRANCISCO, July 19, 2021 (GLOBE NEWSWIRE) -- Eluminex Biosciences (Suzhou) Limited (Eluminex), an ophthalmology-focused biotechnology company headquartered in Suzhou, China with a ...

6 days ago - GlobeNewsWire

An FDA advisory committee made it clear that they don't want the agency to approve roxadustat due to safety concerns.

1 week ago - The Motley Fool

FibroGen (FGEN) stock is falling hard on Friday after the company received the results of an FDA review for one of its drugs. The post FGEN Stock: The Huge FDA News Causing FibroGen Shares to Free Fall ...

1 week ago - InvestorPlace

FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.

1 week ago - Zacks Investment Research

FibroGen, Inc. (NASDAQ: FGEN) shares are trading lower after an FDA Advisory Committee panel voted against approval of the company's New Drug Application for roxadustat to treat anemia due to chronic ki...

1 week ago - Benzinga

FibroGen, Inc.'s (NASDAQ: FGEN) shares are sinking to their lowest level since late June 2016. FibroGen's AdCom Snub  FibroGen said late Thursday the Food and Drug Administration's Cardiovascular and Re...

1 week ago - Benzinga

Yesterday, the U.S. FDA voted not to approve Roxadustat for the treatment of anemia due to chronic kidney disease in adult patients.

1 week ago - Forbes

SAN FRANCISCO, July 15, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) ...

1 week ago - GlobeNewsWire

FibroGen, Inc. (NASDAQ:FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. ...

1 week ago - Benzinga

Ahead of Thursday's meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee, the agency is raising fresh doubts on the safety of AstraZeneca Plc's (NASDAQ: AZN) and FibroGen Inc's (NASDAQ...

Other stocks mentioned: AZN
1 week ago - Benzinga

SAN FRANCISCO, July 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGen's...

1 week ago - GlobeNewsWire

TOKYO, June 25, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today...

1 month ago - GlobeNewsWire

FibroGen Inc (NASDAQ: FGEN) and HiFiBiO Therapeutics have entered into a licensing agreement for three programs in the immuno-oncology and autoimmune space. FibroGen exclusively in-licenses HiFiBiO's Ga...

1 month ago - Benzinga

SAN FRANCISCO and CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with experti...

1 month ago - GlobeNewsWire

SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision Promise SM adaptiv...

1 month ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain ...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - June 11, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against Fibro...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 11, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or "the Company...

1 month ago - Newsfile Corp

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Cor...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 10, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that ...

1 month ago - Newsfile Corp

LOS ANGELES, June 10, 2021 /PRNewswire/ -- The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("Fibro...

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - June 10, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Fibr...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - June 10, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against Fibro...

1 month ago - Newsfile Corp

Radnor, Pennsylvania--(Newsfile Corp. - June 10, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 9, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders FibroGen, Inc. (NASDAQ: FGEN).CLICK HE...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 9, 2021) -  The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN).Sha...

1 month ago - Newsfile Corp

NEW YORK, June 9, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and April 6,...

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - June 9, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("Fibr...

1 month ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $FGEN #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

1 month ago - Business Wire

Los Angeles, California--(Newsfile Corp. - June 9, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroG...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 9, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that t...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Fibro...

1 month ago - Newsfile Corp

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Cor...

1 month ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - June 8, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroG...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 8, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securiti...

1 month ago - Newsfile Corp

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Cor...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain o...

1 month ago - Newsfile Corp

Radnor, Pennsylvania--(Newsfile Corp. - June 5, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen,...

1 month ago - Newsfile Corp

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Cor...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 2, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 20...

1 month ago - Newsfile Corp

Radnor, Pennsylvania--(Newsfile Corp. - June 2, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") that a securities fraud class a...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - June 2, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN).Shar...

1 month ago - Newsfile Corp

RADNOR, Pa., June 1, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ:...

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - June 1, 2021) -  The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("Fib...

1 month ago - Newsfile Corp

NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers....

1 month ago - PRNewsWire

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Cor...

1 month ago - Newsfile Corp

NEW YORK, May 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and April 6,...

1 month ago - PRNewsWire

Radnor, Pennsylvania--(Newsfile Corp. - May 29, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen,...

1 month ago - Newsfile Corp

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Cor...

1 month ago - Newsfile Corp

About FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inh... [Read more...]

Industry
Biotechnology
IPO Date
Nov 14, 2014
CEO
Enrique Conterno
Employees
599
Stock Exchange
NASDAQ
Ticker Symbol
FGEN
Full Company Profile

Financial Performance

In 2020, FibroGen's revenue was $176.32 million, a decrease of -31.28% compared to the previous year's $256.58 million. Losses were -$189.29 million, 145.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for FibroGen stock is "Buy." The 12-month stock price forecast is 36.71, which is an increase of 176.64% from the latest price.

Price Target
$36.71
(176.64% upside)
Analyst Consensus: Buy